Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?

International journal of molecular sciences - 12 May 2021

McKenna Stephanie, García-Gutiérrez Lucía

Abstract excerpt

Melanoma is one of the most aggressive forms of skin cancer and is therapeutically challenging, considering its high mutation rate. Following the development of therapies to target BRAF, the most frequently found mutation in melanoma, promising therapeutic responses were observed. While mono- and combination therapies to target the MAPK cascade did induce a therapeutic response in BRAF-mutated melanomas, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Melanoma
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 34066022
DOI: 10.3390/ijms22105115
PMCID: PMC8150731

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?PMID 34066022Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current KnowledgeSemantic proximity Read ↗

MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.Semantic proximity Read ↗

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read ↗

Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma.Semantic proximity Read ↗

BRAF inhibitors: resistance and the promise of combination treatments for melanomaSemantic proximity Read ↗

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.Semantic proximity Read ↗

Overcoming resistance to BRAF inhibitorsSemantic proximity Read ↗

Targeting BRAF in melanoma: biological and clinical challenges.Semantic proximity Read ↗

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanomaSemantic proximity Read ↗

BRAF Gene and Melanoma: Back to the Future.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An UpdateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.